A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants

Part of paid clinical trials in Lenexa, Kansas.

Sponsor
Eli Lilly and Company
Study ID
NCT07592572
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • LY4395089 — DRUG
    Administered orally
  • Itraconazole — DRUG
    Administered orally
  • Itraconazole — DRUG
    Administered orally

Study Details

The purpose of the study is to see how itraconazole affects LY4395089 in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. There will be fifteen inpatient stays at the clinical research unit (CRU). The study will last about 2 weeks.

Key Dates

First listed
May 18, 2026
Start date
May 20, 2026
Status verified
Jun 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
14 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY4395089
    LY4395089 administered orally
  • Experimental: Itraconazole
    Itraconazole administered orally
  • Experimental: LY4395089 + Itraconazole
    LY4395089 and Itraconazole administered orally

Primary Outcome Measure

Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from 0 to infinity (AUC[0-∞]) of LY4395089 [ Time Frame: Baseline up to Day 15 ]

Central Contacts

  • Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
    1-317-615-4559
    [email protected]
  • Physicians interested in becoming principal investigators please contact
    [email protected]

Locations (1)

FacilityCityStateZIPSite coordinators
Lenexa ClinicLenexaKansas66219
913-574-6457
Patrick Yao (PRINCIPAL_INVESTIGATOR)

Find similar trials in Lenexa, KS

By research site
Lenexa Clinic· Lenexa, KS

Related Studies